Sunday, July 12, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 51 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 10125131

    Selective HDAC3 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted
  2. US 10125128

    GLS1 inhibitors for treating disease

    The Board of Regents of the University of Texas System · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted
  3. US 10123984

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted
  4. US 10125102

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted
  5. US 10125134

    KRas G12C inhibitors

    Mirati Therapeutics, Inc. · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted
  6. US 10117945

    mTORC1 inhibitors

    The Regents of the University of California · Granted Nov 6, 2018 · Expires Nov 1, 2038

    granted
  7. US 10117871

    3-hydroxypyrimidine-2,4-dione-5-carboxamides as potent inhibitors of HIV

    Regents of the University of Minnesota · Granted Nov 6, 2018 · Expires Nov 1, 2038

    granted
  8. US 10111878

    N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer

    Agios Pharmaceuticals, Inc. · Granted Oct 30, 2018 · Expires Oct 25, 2038

    granted
  9. US 10111953

    Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 30, 2018 · Expires Oct 25, 2038

    granted
  10. US 10106538

    Inhibitors of protein kinases

    Princeton Drug Discovery, Inc · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted
  11. US 10106569

    Inhibitors of sodium glucose transporter 1 for constipation

    LEXICON PHARMACEUTICALS, INC. · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted
  12. US 10106540

    HDAC6 inhibitors and their uses

    Universität Regensburg · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted
  13. US 10100049

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Theravance Biopharma R&D IP, LLC · Granted Oct 16, 2018 · Expires Oct 11, 2038

    granted
  14. US 10098878

    HIF-2α inhibitors for treating iron overload disorders

    The Board of Regents of the University of Texas System · Granted Oct 16, 2018 · Expires Oct 11, 2038

    granted
  15. US 10093684

    Substituted imidazo[1,2-a]pyrazines as Syk inhibitors

    GILEAD CONNECTICUT, INC. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted
  16. US 10093664

    Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease

    The Board of Regents of the University of Texas System · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted
  17. US 10093629

    Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors

    Takeda Pharmaceutical Company Limited · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted
  18. US 10092656

    Protease inhibitors having enhanced features

    Nektar Therapeutics · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted
  19. US 10092583

    Imidazopyridines Syk inhibitors

    GILEAD CONNECTICUT, INC. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted
  20. US 10093668

    Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2)

    Northwestern University · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted
  21. US 10093676

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted
  22. US 10093686

    Heteroaryl inhibitors of PDE4

    Tetra Discovery Partners · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted
  23. US 10087181

    Compound as WNT signaling inhibitor, composition, and use thereof

    Curegenix, Inc. · Granted Oct 2, 2018 · Expires Sep 27, 2038

    granted
  24. US 10085990

    Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors

    VTV THERAPEUTICS LLC · Granted Oct 2, 2018 · Expires Sep 27, 2038

    granted